Saint Lambert

Researchers are evaluating a method to improve early detection of ovarian and endometrial cancers in women aged 45 years and older who have symptoms like bloating, abdominal or pelvic pain, increased urinary frequency, or early fullness after eating. The study aims to see if earlier surgery guided by screening tests can benefit these women by diagnosing cancer at an early, curable stage. Participants undergo a CA-125 blood test and a transvaginal ultrasound at the start of the study, with a second CA-125 blood test six weeks later. A follow-up phone call occurs six months after the last visit to check on participants' health. During the study, researchers track the proportion of participants diagnosed with early-stage cancer over up to three years. The study involves symptom monitoring, blood biomarker testing, ultrasound imaging, and health status verification through phone follow-up to assess the effectiveness of early detection strategies.

Researchers are investigating whether the medicine vicadrostat, when taken together with empagliflozin, can lower the risk of heart-related problems in adults who have type 2 diabetes, high blood pressure, and cardiovascular disease but no history of heart failure. This study is a Phase III trial that compares the effects of vicadrostat plus empagliflozin to a placebo plus empagliflozin in people with these conditions. Participants are randomly assigned to one of two groups: one group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets that look like vicadrostat along with empagliflozin. All participants take one tablet daily for a period ranging from two and a half years up to four years and three months. Throughout the study, participants continue their usual medications for diabetes, high blood pressure, and cardiovascular disease. During up to 51 months of participation, participants visit the study site regularly where doctors collect health information and blood samples. Researchers track when participants experience cardiovascular events such as heart-related deaths or heart failure events. The study also monitors participants’ overall health and any side effects they may experience to assess the safety and effects of the treatments.